PATENT CLAIM ANALYSIS

Application Number: 15902437
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "043000"]

Abstract:
The present invention relates to a prodrug of 5-azacytidine or 2′-deoxy-5-azacytidine having remarkable stability against cytidine deaminase, a metabolic hydrolyzing enzyme in replacement of current injections (5-azacytidine or 2′-deoxy-5-azacytidine) which are clinically used as therapeutic agents for various myelomas including myelodysplastic syndrome. The present invention provides a compound represented by formula (1), or salt thereof, wherein, R is OR 3  or a hydrogen atom, R 1 , R 2 , and R 3  are each independently hydrogen atom or silyl group represented by formula (2): wherein, R 4 , R 5 , and R 6  are each independently alkyl group which may have a substituent, aryl group which may have a substituent, or arylalkyl group which may have a substituent, with the provision that R 1 , R 2 , and R 3  are not hydrogen atom simultaneously.

Claim (Index 14):
A pharmaceutical composition, which comprises the compound, or salt thereof, according to  claim 7 .

Metadata:
- Claim Count in Document: 35.0
- Percentile: 88.0
- Lexical Diversity: 2.0
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15355315', '15355326', '11815149', '11887159', '14057004']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7929505477284462
- 35 USC 102 Novelty (BERT): 0.5694298342932719
- Combined Prediction Score: 0.7705984763849287
- Mean Citation Score: 316.272016
- Max Citation Score: 485.39816
- Similarity Product: 352.6404490335178

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test